Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $269 to $231.
Goldman Sachs Maintains Buy on Moderna, Lowers Price Target to $231
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.